AAT 008Alternative Names: AAT-008
Latest Information Update: 28 Jul 2016
At a glance
- Originator AskAt
- Mechanism of Action Prostaglandin E EP4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer; Contact dermatitis; Inflammatory bowel diseases; Osteoarthritis; Psoriasis